Arca
Skip to content
Tools
Tools

Glycogen

Oligosaccharide in Homo sapiens that 2 drugs act on.

  • Drugs that act on it: 2
  • Approved: 2
  • In phases 1 to 3: 0
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on this target, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Protein or peptide 2

Approved2

  • Avalglucosidase alfa
  • Cipaglucosidase alfa

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        Avalglucosidase alfaBoxed warningApprovedSanofiProtein or peptideHydrolytic enzymeGlycogen hydrolytic enzyme8
        Cipaglucosidase alfaBoxed warningApprovedAmicus Therapeutics USProtein or peptideHydrolytic enzymeGlycogen hydrolytic enzyme3

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 10 in all, from ClinicalTrials.gov.
        Safety and Efficacy of Avalglucosidase Alfa in Patients With Non-classic Pompe Disease Aged ≥ 5 YearsAvalglucosidase alfaPhase 4Active, not recruitingIris PlugJun 17, 2026
        China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPDAvalglucosidase alfaPhase 4RecruitingGenzyme, a Sanofi CompanyOct 30, 2024
        A Global Prospective Observational Registry of Patients With Pompe DiseaseAvalglucosidase alfa, Cipaglucosidase alfa—RecruitingAmicus TherapeuticsNov 7, 2023
        Avalglucosidase Alfa Pregnancy StudyAvalglucosidase alfa—RecruitingSanofiFeb 21, 2023
        Avalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA Avalglucosidase)Avalglucosidase alfaPhase 4Active, not recruitingGenzyme, a Sanofi CompanyDec 20, 2021
        Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase AlfaAvalglucosidase alfaPhase 3Active, not recruitingSanofiJun 2, 2021
        A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18Cipaglucosidase alfaPhase 3RecruitingAmicus TherapeuticsMar 22, 2021
        ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPDCipaglucosidase alfaPhase 3Active, not recruitingAmicus TherapeuticsApr 11, 2019
        A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase AlfaAvalglucosidase alfaPhase 2Active, not recruitingGenzyme, a Sanofi CompanyJan 12, 2017
        Pompe Pregnancy Sub-RegistryAvalglucosidase alfa—RecruitingGenzyme, a Sanofi CompanyDec 4, 2007

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4662969, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.